Clinical Effectiveness of the Cardiovascular Polypill in a Real-Life Setting in Patients with Cardiovascular Risk: The SORS Study

Reaching Blood Pressure Guideline Targets With the CNIC Polypill in Patients With a Previous Cardiovascular Event in Mexico: A post hoc Analysis of the Sors Study

“…This subanalysis showed that switching from usual care to a polypill strategy could facilitate achieving the 2016 ESC guideline targets for BP in a real-life setting of patients with cardiovascular disease, as a result of the better control of BP observed in the original SORS study [17]. According to the ESC guidelines, achievement of the BP target (SBP <140 mmHg and DBP <90 mmHg in all treated hypertensive patients <60 years old, with slight differences depending on age and clinical condition) is essential for prevention of cardiovascular disease in clinical practice [12].…”

“…From a total of 1193 patients included in the SORS study [17], 572 (47.9%) had cardiovascular disease and were included in the analysis. Table 1 shows the demographic and clinical characteristics of the study population.…”

“…The design of this study is addressed elsewhere [17]. Briefly, SORS was a multicenter, observational and prospective study of a single cohort of patients in Mexico who initiated treatment with the CNIC polypill for prevention of cardiovascular events based on the criteria of the attending physician.…”

“…SORS is the first study to evaluate the effectiveness of the CNIC polypill in patients at high cardiovascular risk in clinical practice. The results showed that this strategy was associated with improvements in blood pressure (BP) and LDL cholesterol targets, independently of baseline treatment [17]. With this post hoc analysis, we assessed whether the switch to CNIC polypill from usual care in patients with cardiovascular disease facilitates achievement of the 2016 European Society of Cardiology (ESC) guideline targets for BP under conditions of daily clinical practice.…”

The CNIC-polypill improves atherogenic dyslipidemia markers in patients at high risk or with cardiovascular disease: Results from a real-world setting in Mexico

“…aspirin, ramipril, and atorvastatin/simvastatin) was the first CV polypill approved and marketed for the secondary prevention of CVD [6] , [9] . A recent real-world, prospective, observational study conducted in Mexico (SORS study) in patients with or at high risk of CVD reported that, after one year of treatment with the CNIC-polypill, there were significant reductions in systolic and diastolic BP, total cholesterol (TC), LDL–c, triglycerides (TG), and an increase in high-density lipoprotein cholesterol (HDL–c) [10] . In clinical practice, and beyond lifestyle recommendations, LDL–c reduction is the primary target in the management of dyslipidemia and reduction of cardiovascular risk (CVR), with statins as the first line lipid-lowering therapy [1] .…”